| 2025-11-14 |
详情>>
内部人交易：
HAZEN SAMUEL N股份减少14830.00股
|
| 2025-10-30 |
详情>>
股本变动：
变动后总股本22819.39万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益20.47美元,归母净利润49.06亿美元,同比去年增长13.51%
|
| 2025-08-04 |
详情>>
业绩披露：
2025年中报每股收益13.43美元,归母净利润32.63亿美元,同比去年增长6.91%
|
| 2025-07-25 |
财报披露：
美东时间 2025-07-25 盘前发布财报
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益6.52美元,归母净利润16.10亿美元,同比去年增长1.19%
|
| 2025-03-14 |
股东大会：
将于2025-04-24召开股东大会
会议内容 ▼▲
- 1.To elect nine nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2026 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025;
3.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
4.To approve the First Amendment to the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates;
5.To approve an amendment to the Company’s amended and restated certificate of incorporation to provide for the exculpation of officers as permitted by Delaware law;
6.To consider and vote upon a stockholder proposal regarding lavish golden parachutes;
7.To consider and vote upon a stockholder proposal regarding an amendment to the Patient Safety and Quality of Care Committee charter;
8.To consider and vote upon a stockholder proposal regarding a report on acquisition strategy;
9.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2025-02-14 |
详情>>
业绩披露：
2022年年报每股收益19.43美元,归母净利润56.43亿美元,同比去年增长-18.88%
|
| 2025-02-14 |
详情>>
业绩披露：
2024年年报每股收益22.27美元,归母净利润57.60亿美元,同比去年增长9.88%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益16.57美元,归母净利润43.22亿美元,同比去年增长18.90%
|
| 2024-07-29 |
详情>>
业绩披露：
2023年中报每股收益9.27美元,归母净利润25.56亿美元,同比去年增长5.27%
|
| 2024-07-29 |
详情>>
业绩披露：
2024年中报每股收益11.61美元,归母净利润30.52亿美元,同比去年增长19.41%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益6.01美元,归母净利润15.91亿美元,同比去年增长16.73%
|
| 2024-03-15 |
股东大会：
将于2024-04-25召开股东大会
会议内容 ▼▲
- 1.To elect ten nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2025 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024;
3.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
4.To conduct an advisory (non-binding) vote to approve the frequency of future say-on-pay votes;
5.To consider and vote upon a stockholder proposal regarding a report on risk mitigation regarding state restrictions for emergency abortions;
6.To consider and vote upon a stockholder proposal regarding a report on maternal health outcomes;
7.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2024-02-16 |
详情>>
业绩披露：
2023年年报每股收益19.25美元,归母净利润52.42亿美元,同比去年增长-7.11%
|
| 2023-10-26 |
详情>>
业绩披露：
2023年三季报(累计)每股收益13.26美元,归母净利润36.35亿美元,同比去年增长2.05%
|
| 2023-03-10 |
股东大会：
将于2023-04-19召开股东大会
会议内容 ▼▲
- 1.To elect ten nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2024 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023;
3.To approve the HCA Healthcare, Inc. 2023 Employee Stock Purchase Plan;
4.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
5.To consider and vote upon a stockholder proposal regarding political spending disclosure;
6.To consider and vote upon a stockholder proposal regarding an amendment to the Patient Safety and Quality of Care Committee charter;
7.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2022-03-11 |
股东大会：
将于2022-04-21召开股东大会
会议内容 ▼▲
- 1.To elect eleven nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2023 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022;
3.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
4.To consider and vote upon a stockholder proposal regarding political spending disclosure;
5.To consider and vote upon a stockholder proposal regarding lobbying disclosure;
6.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-19 |
股东大会：
将于2021-04-28召开股东大会
会议内容 ▼▲
- 1.To elect nine nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2022 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021;
3.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
4.To consider and vote upon a stockholder proposal regarding stockholders’ ability to act by written consent;
5.To consider and vote upon a stockholder proposal requesting a report on the feasibility of increasing the impact of quality metrics on executive compensation;
6.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2020-03-23 |
复牌提示：
2020-03-23 09:37:30 停牌，复牌日期 2020-03-23 09:43:40
|
| 2020-03-20 |
股东大会：
将于2020-05-01召开股东大会
会议内容 ▼▲
- 1.To elect nine nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2021 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020;
3.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
4.To approve the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates;
5.To approve an amendment to the Company’s amended and restated certificate of incorporation to allow certain stockholders to request special meetings of stockholders;
6.To consider and vote upon a stockholder proposal regarding stockholders’ ability to act by written consent;
7.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2020-01-28 |
除权日：
美东时间 2020-02-28 每股派息0.43美元
|
| 2019-10-29 |
除权日：
美东时间 2019-11-29 每股派息0.40美元
|
| 2019-07-29 |
除权日：
美东时间 2019-08-30 每股派息0.40美元
|
| 2019-04-30 |
除权日：
美东时间 2019-05-31 每股派息0.40美元
|
| 2019-03-15 |
股东大会：
将于2019-04-26召开股东大会
会议内容 ▼▲
- 1.To elect eleven nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2020 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019;
3.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
4.To approve amendments to the Company’s amended and restated certificate of incorporation to eliminate supermajority voting requirements;
5.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2019-01-29 |
除权日：
美东时间 2019-02-28 每股派息0.40美元
|
| 2018-10-30 |
除权日：
美东时间 2018-11-30 每股派息0.35美元
|
| 2018-07-25 |
除权日：
美东时间 2018-08-31 每股派息0.35美元
|
| 2018-05-01 |
除权日：
美东时间 2018-05-31 每股派息0.35美元
|
| 2018-03-16 |
股东大会：
将于2018-04-26召开股东大会
会议内容 ▼▲
- 1.To elect eleven nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2019 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018;
3.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
4.To conduct an advisory (non-binding) vote to approve the frequency of future say-on-pay votes;
5.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2018-01-29 |
除权日：
美东时间 2018-02-28 每股派息0.35美元
|
| 2017-03-17 |
股东大会：
将于2017-04-27召开股东大会
会议内容 ▼▲
- 1.To elect eleven nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2018 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2017;
3.To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
4.To approve an amendment to the Company’s amended and restated certificate of incorporation to allow certain stockholders to request special meetings of stockholders;
5.To consider and vote upon a stockholder proposal regarding special shareowner meetings, if properly presented;
6.To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2016-03-17 |
股东大会：
将于2016-04-28召开股东大会
会议内容 ▼▲
- 1. To elect twelve nominees for director of the Company, nominated by the Board of Directors, with each director to serve until the 2017 annual meeting of the stockholders of the Company or until such director’s respective successor is duly elected and qualified;
2. To reapprove, for purposes of Section 162(m) of the Internal Revenue Code, the material terms of the performance goals under the 2006 Stock Incentive Plan for Key Employees of HCA Holdings, Inc. and its Affiliates, as Amended and Restated;
3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2016;
4. To approve, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement (“say-on-pay”);
5. To consider and vote upon a stockholder proposal regarding a majority vote standard for the election of directors, if properly presented;
6. To transact such other business as may properly come before the meeting or any postponement or adjournment of the meeting.
|
| 2012-12-06 |
除权日：
美东时间 2012-12-13 每股派息2.00美元
|
| 2012-10-23 |
除权日：
美东时间 2012-10-31 每股派息2.50美元
|
| 2012-02-06 |
除权日：
美东时间 2012-02-14 每股派息2.00美元
|